Updates are available Correction dated 2018-09-03

Article History

Received: 20 April 2018

Accepted: 16 July 2018

First Online: 24 July 2018

Change Date: 3 September 2018

Change Type: Correction

Change Details: Ad-HBV is a product (T101) aiming to treat chronic HBV firstly developed by Transgene S.A., France then by Transgene Tasly (Tianjin) Biopharmaceutical Co., Ltd., Tianjin, China in China.

Ethical approval

: The animal experiments were conducted in a GLP-compliant and AAALAC-accredited laboratory (Jiangsu Tripod Preclinical Research Laboratories Co., Ltd., Nanjing, China), and all study protocols were approved by the testing facility’s Institutional Animal Care and Use Committee.

: The authors declare that there are no competing interest regarding the publication of this paper.

: Not applicable.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.